Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOSITE TOPICAL SYSTEM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE versus LIDOSITE TOPICAL SYSTEM KIT.
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE vs LIDOSITE TOPICAL SYSTEM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also exhibits cardiac effects as a class IB antiarrhythmic agent by modulating sodium channels in myocardial cells.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
1-4 mg/kg via intravenous bolus, not to exceed 300 mg; may be followed by continuous infusion of 1-4 mg/min.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
None Documented
None Documented
1.5–2 hours (terminal) in healthy adults; prolonged in hepatic impairment (up to 5–7 hours), heart failure (up to 10 hours), or with continuous infusion (>24 h) due to accumulation. Context: requires monitoring in hepatic or cardiac dysfunction to avoid toxicity.
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Renal: ~90% as metabolites (primarily monoethylglycinexylidide [MEGX] and glycinexylidide [GX]), <10% unchanged. Fecal: <1%.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic